What Happens When You Stop a GLP-1 (and How to Keep the Weight Off)

What the Withdrawal Trials Actually Show

Like a blood-pressure medication, a GLP-1 generally works while you're taking it — that's not a flaw in the drug, it's simply how the biology works. The most useful thing about GLP-1 research is that we do not have to guess what happens after people stop. Several large trials deliberately withdrew the medication and tracked what followed. The pattern is consistent, and it is worth understanding before you make any decision.

The clearest data comes from the STEP 1 trial extension. In the original study, adults with overweight or obesity lost an average of 17.3% of their body weight over 68 weeks on semaglutide 2.4 mg. Researchers then followed a group of participants for a year after both the medication and the structured lifestyle support were withdrawn. One year later, they had regained about two-thirds of the weight they had lost, and the improvements in blood pressure, cholesterol, and blood sugar largely reverted as well. The authors framed the takeaway plainly: this confirms the chronicity of obesity and suggests ongoing treatment is generally needed to maintain the results.

The STEP 4 trial approached the question from a different angle. Everyone took semaglutide for a 20-week run-in, then half were randomly switched to placebo. Over the next 48 weeks, the people who kept taking semaglutide lost an additional 7.9% on average, while those switched to placebo regained about 6.9%. Same starting point, opposite trajectories, and the only difference was whether treatment continued.

Tirzepatide shows the same shape. In SURMOUNT-4, participants took tirzepatide for a 36-week lead-in and lost about a fifth of their body weight, then were randomized to continue or switch to placebo. By the end of the study, the continued group was down 25.3% while the placebo group had drifted back to 9.9% — meaning those who stopped regained roughly 14% of their body weight over the following year.

Read together, these trials deliver one honest message: for most people, the weight loss is real but not self-sustaining once the drug is gone. That is not a personal failing. It is the biology of a chronic condition.

Why the Weight Comes Back

GLP-1 medications work largely by turning down appetite — the physical hunger and the mental "food noise" that pulls attention back to eating. They do this while you take them. They do not permanently reset the systems that regulate body weight.

Your body defends a weight range. After you lose a significant amount of weight, appetite-regulating signals push toward eating more, and the amount of energy you burn at rest tends to fall somewhat relative to your new size. On the medication, that pressure is held in check. When the medication clears — and semaglutide and tirzepatide leave the body over a matter of weeks — the appetite suppression fades, hunger and cravings return, intake rises, and weight tends to climb back toward where the body was defending it.

This is why framing matters. Stopping a GLP-1 is less like finishing a course of antibiotics and more like stopping a blood pressure medication: the underlying condition is still there, so the numbers tend to move back. Understanding that in advance is the difference between feeling blindsided and having a plan.

The Muscle Question: Protect It Before You Stop

Rapid weight loss of any kind — from a GLP-1, from surgery, or from aggressive dieting — costs some muscle along with fat. By some estimates a quarter or more of the weight lost can be lean tissue if nothing is done to protect it. That matters twice over: muscle supports strength and day-to-day function, and it is metabolically active, so losing it makes maintaining a lower weight harder later.

The encouraging part is that muscle loss is largely modifiable. The two levers with the best evidence are adequate protein and resistance training, and both are worth putting in place well before you consider stopping — ideally from the start of treatment. Our nutrition guide for GLP-1 therapy goes deeper on hitting protein targets when your appetite is low.

A Concrete Plan to Blunt the Rebound

If you and your prescriber decide to reduce or stop, going in with a structured plan changes the odds. None of the following is exotic — the value is in doing it consistently through the transition, not perfectly.

1. Make protein the anchor of every meal

A common target for people on GLP-1 therapy is roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day, prioritized so that protein comes first at each meal. When appetite is still low, a whey or plant protein shake is an efficient way to close the gap without forcing a large meal. Adequate protein supports the muscle you are trying to keep and helps with satiety as natural hunger returns.

2. Lift something twice a week, minimum

Resistance training is the single most effective way to hold onto muscle during and after weight loss. You do not need a complicated program. Two or more sessions a week built around compound movements — squats, hinges, presses, rows, in whatever form fits your body and access — covers most of the benefit. If you are new to it or over 50, starting with a trainer or physical therapist is reasonable.

3. Keep the eating structure you built

Many people develop genuinely useful habits on a GLP-1: smaller portions, more protein, less alcohol, fewer ultra-processed snacks. Those habits do not disappear when the medication does. Holding the structure — regular meals, protein first, vegetables and fiber, limited liquid calories — is what carries the weight-management effect forward once the pharmacological appetite brake is gone.

4. Watch the trend, not the daily number

Weight fluctuates day to day. What you want to catch is a sustained upward drift over two to four weeks, because early is when it is easiest to respond — with a nutrition tune-up, more training, or a conversation about restarting or a maintenance dose. Weighing weekly and looking at the trend is more useful than daily check-ins that mostly measure water.

5. Talk about the tapering question honestly

It is reasonable to ask whether stepping the dose down gradually helps. Be aware that the direct evidence is limited: the major withdrawal trials stopped the drug abruptly rather than tapering, so we cannot claim that tapering prevents regain. It may make the transition feel smoother, and some prescribers use it, but the better-established levers remain nutrition, resistance training, and — for many people — continuing on a lower maintenance dose.

The Timeline After You Stop

When Staying On (or Going Back On) Is the Right Call

There is no prize for being off medication if your health is better on it. For many people with obesity, GLP-1 therapy is best understood as long-term treatment for a chronic condition, and continuing — sometimes at a lower maintenance dose — is a legitimate, evidence-supported choice rather than a fallback. The withdrawal trials make the case almost mechanically: the people who kept taking the medication kept the results, and the cardiometabolic benefits held only while treatment continued.

Reasons you might stop are still valid — cost, side effects, pregnancy planning, or simply reaching a stable place with your prescriber's blessing. The point is that the decision belongs in a conversation with your provider, framed as chronic-disease management, not as a pass/fail test of willpower. If you are still weighing options or comparing programs, our reviews of GLP-1 providers and the two-minute eligibility quiz can help you think it through.

The Bottom Line

Stopping a GLP-1 usually brings back some appetite and some weight — the trials are consistent on that, and pretending otherwise helps no one. But "some regain is common" is not the same as "regain is guaranteed to be total." The size of the rebound depends heavily on what you do: protecting muscle with protein and resistance training, keeping the eating structure you built, catching an upward trend early, and treating the whole thing as a chronic-condition decision made with your prescriber rather than a solo experiment. Go in with a plan, and you keep far more of what you worked for.

Frequently Asked Questions

Will I regain the weight if I stop a GLP-1?

Some regain is likely for most people. In the STEP 1 trial extension, participants regained about two-thirds of their lost weight within a year of stopping semaglutide. Regain is not inevitable in full, though — protein-forward eating, resistance training, and a maintenance plan made with your prescriber can meaningfully slow it.

How fast does weight come back after stopping a GLP-1?

Appetite and food cravings usually return within a few weeks as the medication clears. Weight regain then tends to build gradually over the following months. In the STEP 1 extension, most of the two-thirds regain occurred over the year after withdrawal.

Does tapering the dose prevent weight regain?

There is not yet strong direct evidence that gradual tapering prevents regain — the major withdrawal trials stopped the drug abruptly. Tapering may make the transition feel smoother and is commonly used in practice, but the more established levers for holding weight are nutrition, resistance training, and, for many people, staying on a maintenance dose.

Why does weight come back after stopping a GLP-1?

Obesity is a chronic condition, and GLP-1 medications manage appetite rather than cure it. When the drug is withdrawn, appetite signaling and the body's tendency to defend a higher weight reassert themselves, so intake rises and weight tends to climb back toward its prior set point.

Is it okay to stay on a GLP-1 long term?

For many people with obesity, long-term or maintenance-dose therapy is a reasonable, evidence-supported approach, much like ongoing treatment for blood pressure. Whether to continue, lower the dose, or stop is a decision to make with your prescriber based on your health, goals, and how you respond.

Related Articles

• How to Stop a GLP-1 Without Gaining Weight Back: Nutrition Guide
• Understanding GLP-1 Side Effects: A Complete Management Guide
• GLP-1 Provider Reviews Compared
• Take the 2-Minute GLP-1 Eligibility Quiz

References

• Wilding JPH, Batterham RL, Davies M, et al. (2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism, 24(8):1553-1564. DOI: 10.1111/dom.14725. — One year after withdrawal, participants regained about two-thirds of prior weight loss.
• Rubino D, Abrahamsson N, Davies M, et al. (2021). "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial." JAMA, 325(14):1414-1425. DOI: 10.1001/jama.2021.3224. — Continued treatment lost a further 7.9%; switching to placebo regained 6.9%.
• Aronne LJ, Sattar N, Horn DB, et al. (2024). "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial." JAMA, 331(1):38-48. DOI: 10.1001/jama.2023.24945. — Continued group reached 25.3% total loss vs 9.9% for those switched to placebo.
• Neeland IJ, et al. (2025). "GLP-1 agonists and exercise: the future of lifestyle prioritization." Frontiers in Clinical Diabetes and Healthcare. DOI: 10.3389/fcdhc.2025.1720794. — Review of resistance training and protein for preserving lean mass during GLP-1-induced weight loss.
• Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series (2025). PubMed Central, PMC12536186. — Documents lean-mass outcomes and the role of structured activity and protein intake.